Last reviewed · How we verify
DSP
DSP is a liposomal doxorubicin formulation that delivers the chemotherapy agent doxorubicin within lipid nanoparticles to improve drug targeting and reduce systemic toxicity.
DSP is a liposomal doxorubicin formulation that delivers the chemotherapy agent doxorubicin within lipid nanoparticles to improve drug targeting and reduce systemic toxicity. Used for Metastatic breast cancer, Ovarian cancer, Multiple myeloma.
At a glance
| Generic name | DSP |
|---|---|
| Also known as | Dexamethasone Sodium Phosphate |
| Sponsor | Taiwan Liposome Company |
| Drug class | Liposomal anthracycline chemotherapy |
| Target | Topoisomerase II |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | FDA-approved |
Mechanism of action
The liposomal encapsulation of doxorubicin allows for preferential accumulation in tumor tissues through the enhanced permeability and retention (EPR) effect, while reducing exposure to healthy tissues. This formulation approach decreases cardiotoxicity and other dose-limiting side effects associated with free doxorubicin, allowing for improved therapeutic efficacy.
Approved indications
- Metastatic breast cancer
- Ovarian cancer
- Multiple myeloma
Common side effects
- Myelosuppression
- Nausea and vomiting
- Alopecia
- Palmar-plantar erythrodysesthesia
- Infusion reactions
Key clinical trials
- Open-Label Extension of EryDex Study IEDAT-04-2022 (PHASE3)
- An Efficacy and Safety Study of DFL24498 in the Treatment of AKC (PHASE3)
- Feasibility Study of Diaphragm Synchronized Pacing (DSP) Via the Left Inferior Phrenic Vein (LIPV) Approach (NA)
- Evaluate the Neurological Effects of EryDex on Subjects With A-T (PHASE3)
- PReventive Effect Of Left Bundle Branch Area Pacing Versus righT vEntricular paCing on All Cause deaTh, Heart Failure Progression, and Ventricular dysSYNChrony in Patients With Substantial Ventricular Pacing (PROTECT-SYNC): Multicenter Prospective Randomized Controlled Trial (NA)
- Mobilizing Doulas to Empower Black Women in Post-partum Diabetes Prevention (NA)
- DHF-20-1839-2: Clinical Performance Study Protocol for Therascreen® KRAS RGQ PCR Kit (NA)
- Evaluation of Electrical and Hemodynamic Effects of Different Pacing Strategies in CRT Candidates (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |